Intussusception Risk and Disease Prevention Associated With Rotavirus Vaccines in Australia's National Immunization Program
John B Carlin, Kristine K Macartney, Katherine J Lee, Helen E Quinn, Jim Buttery, Ruth Lopert, Julie Bines, Peter B McIntyre
CLINICAL INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2013
BACKGROUND: Estimates of the risk of intussusception (IS) associated with currently licensed rotavirus vaccines (RV1 [Rotarix; GSK] and RV5 [RotaTeq; Merck]) diverge. Contemporaneous introduction of both vaccines in Australia enabled a population-based assessment of risk. METHODS: Confirmed cases of IS in infants aged 1 to <12 months were identified from national hospitalization databases, supplemented by active hospital-based surveillance, from July 2007 through June 2010. Vaccination histories were verified by the Australian Childhood Immunisation Register, which was also used to identify age-matched controls. Self-controlled case series and case-control methods were used to assess the ris..View full abstract
This work was supported by the TGA, Australia's national regulatory agency, which contracted the Murdoch Childrens Research Institute to lead this study, based on data provided by jurisdictional authorities in each of Australia's states and territories, supplemented by data collected by a collaborative research group, the PAEDS network; the PAEDS network is funded by the Australian Government Department of Health and Ageing.